anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: chemistry. ^ SUBSTANCE: method involves treating a water-based medium containing sulphate-reducing bacteria SRB in industrial aqueous systems of chemical production and oil refining. Inhibition of production of biogenic sulphide with SRB takes place as a result of synergetic action of a biocide component in a first concentration and a metabolic inhibitor in a second concentration. The biocide immediately destroys the first portion of SRB. The biocide component is selected from a group comprising aldehydes, amine-type compounds, halogenated compounds, sulphur compounds, salts of quaternary phosphonium and/or combinations thereof. The metabolic inhibitor inhibits growth of a second portion of SRB without its direct destruction. The metabolic inhibitor component is selected from a group comprising nitrite, molybdate, tungstate, selenate, anthraquinone and/or combinations thereof. Contact between the SRB and the biocide and metabolic inhibitor can take place continuously, intermittently or simultaneously. ^ EFFECT: method ensures efficient inhibition of production of biogenic sulphide with SRB during combined use of components in considerably lower concentrations than if the biocide or metabolic inhibitor was used separately. ^ 25 cl, 2 dwg, 1 ex
Healthy, previously untrained, pre-pubertal boys and girls (N=335) were assigned to 16 different groups: 1) physical education, i.e. children participated only school in physical education classes (control group), 2) football (soccer) training, 3) basketball training, 4) volleyball training, 5) wrestling training, 6) martial arts training, 7) tennis training, 8) track and field training, 9) taekwondo training, 10) rhythmic gymnastics training, 11) artistic gymnastics training, 12) dance training, 13) swimming training, 14) climbing training, 15) two weight-bearing training modes, and 16) one weight-bearing and one non-weight bearing activity. Exercise training was performed three times per week for nine months and each training session had a 60-minute duration (except for the physical education classes at school in the control group). Anthropometric measurements (body height, body mass, and length and circumferences of various body segments), blood sampling, measurements of body composition (using dual X-ray energy absorptiometry or DEXA and skinfold calibers), bone measurements (bone density and bone mineral content at lumbar spine, both hips, both wrists and whole body using DEXA), and performance (cardiorespiratory fitness, muscle strength, muscle power, flexibility and motor ability) were performed at baseline and after the completion of a 9-month training intervention. Nutritional intake and habitual physical activity were measured at baseline, mid-training and post-training (using diet recalls and accelerometry, respectively). Intensity and volume of training was measured once every three months using heart rate monitoring, accelerometry, Global Positioning System (GPS) devices and jump measurement. Furthermore, two other studies were also performed as a part of this project: a) assessment of physical activity during physical education classes for primary school (using accelerometry, GPS instrumentation and jump measurement) and b) a smaller number of participants in the football, track and field, swimming and tennis training groups provided blood samples before and after a training session at baseline.
[PROBLEMS] To provide a compound having an excellent inhibitory effect on platelet aggregation. [MEANS FOR SOLVING PROBLEMS] Disclosed is a quinolone derivative having a lower alkyl, a cycloalkyl or the like at the 1-position;-N(R0)C(O)-lower alkylene-CO2R0, a lower alkylene-CO2R0, a lower alkenylene-CO2R0,-O-lower alkenylene-CO2R0,-O-(-lower alkylene which may be substituted by-CO2R0)-aryl,-O-lower alkenylene-CO2R0 (wherein R0 represents H or a lower alkyl) at the 3-position; a halogen at the 6-position; and an amino group substituted by a substituent having a cyclic structure at the 7-position, or a pharmaceutically acceptable salt thereof. It is found that the quinolone derivative has an excellent P2Y12Y-inhibiting effect. It is also found that the quinolone derivative has an excellent inhibitory effect on platelet aggregation. Therefore, the quinolone derivative or the pharmaceutically acceptable salt thereof is useful as a platelet aggregation inhibitor. ® KIPO & WIPO 2009
The control group spent 60 minutes on an online education session (Lilly for Better Health) directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
PURPOSE: Sacral ulcers are a serious mortality risk for older adults; thus, we aimed to determine sacral ulcer risk factors among older adults who were recently admitted to rehabilitation hospitals.
METHOD: We conducted a retrospective cohort study using the Texas Inpatient Discharge database (2021). The study included 1,290 rehabilitation hospital patients aged ≥60 years diagnosed with sacral ulcers. The control group comprised 37,626 rehabilitation hospital patients aged ≥60 years without sacral ulcers. Binary logistic regression was used to identify risks for sacral ulcer development adjusting for patient demographics, insurance type, and lifestyle.
RESULTS: Comorbidities of dementia, Parkinson's disease, type 2 diabetes, and cardiac dysrhythmias were significantly associated with increased risk of sacral ulcers. Longer length of stay, Medicare, and Medicare HMO were also associated with sacral ulcers. Demographically, older age, male sex, identifying as African American, and having malnutrition all had a 50% increased prevalence of sacral ulcers.
CONCLUSION: Findings indicate a need to proactively treat chronic comorbidities in vulnerable populations to reduce their possible risk for hospital-acquired infections and excess mortality from sacral ulcers. [Journal of Gerontological Nursing, 50(2), 32-41.].
Subjects will receive repeated doses of GSK2269577 700mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
A cross-sectional study. A total of 129 congenital cataract patients after congenital cataract extraction (40 in GFCS and 89 in NGFCS) were enrolled in this study from December 2020 to March 2021. All participants, age range from 4 to 18 years old, completed OCT examinations (including macular structure parameters, optic nerve fiber layer thickness periphery retinal nerve fiber layer \[pRNFL\], and sub foveal choroidal thickness \[SFCT\]). All the NGFCS participants underwent OCTA examinations (including vessel density (VD) and perfusion density (PD) of macular and peripapillary area.). Linear regression models were used to examine the effect of various factors on different ocular parameters. Vascular-structural associations were assessed with Spearman correlation. Diagnostic ability was evaluated with area under the receiver operating curve (AUC).
The invention discloses a prescription for treating gestation pruritus. The prescription comprises the following medicinal materials in part by weight: 45-55 parts of common cnidium fruits, 40-50 parts of herba schizonepetae, 80-100 parts of flavescent sophora roots, 20-40 parts of cortex phellodendron and 30-50 parts of divaricate saposhnikovia roots. A making method of the prescription comprises the following steps: step I, weighing the medicinal materials; step II, soaking the weighed medicinal materials; step III, decocting the soaked medicinal materials; and step IV, filtering and cooling. According to the prescription disclosed by the invention, common traditional Chinese medicine materials are used for treating the gestation pruritus, the effects are good, the pain of pregnant women in a gestation period can be eliminated, and serious complications such as premature delivery can be avoided. The gestation pruritus is treated by a method of fumigation and steaming, wet compress and cleaning, so that the problem of side effects caused by oral administration of medicines by the pregnant women can be solved, and the compliance is good. The making method disclosed by the invention is simple, no pain is generated during application, the treatment time is short, and the prescription is convenient for family application of the pregnant women.
The present invention comprises compositions having a.) at least one acetyltransferase EP300 inhibitor-substance, such as chemically pure spermidine or spermidine-rich wheat germ extract, and optionally b.) at least one nrf2 activator-substance, such as cocoa flavonoids. In use, a user typically adds said compositions to food during the day, and then consumes compositions with food. Typically, such additions are scheduled to occur regularly on consecutive days, for months and over years, such as edible bits of sprinkles-configuration added to meals and snacks, or other configurations as herein disclosed. Such compositions are typically consumed by user in divided doses each day, as disclosed herein.
NEW MATERIAL:A compound shown by the formulaI(when dotted line together with solid line shows double bond, R is 1-10C optionally substituted cyclic alkyl; when dotted line together with solid line shown single bond, R is n-propyl or 4-10C optionally substituted cyclic alkyl). EXAMPLE:6-Isobutyl-5H-2,3,6,7-tetrahydro-5,7-dioxothiazolo[3,2-a]pyrim idine. USE:An immune adjustor. Effective for remedying nephritis, autoimmune disease such as nodose rheumatism, etc., or malignant tumor, etc. PROCESS:For example, a compound shown by the formula II (R<1> and R<2> are lower alkyl) and 2-aminothiazoline or 2-aminothiazole are subjected to ring formation through condensation, to give a compound shown by the formulaI. The reaction is carried out in an alcohol in the presence of an alkali metal alkoxide.
Intervention group 2 received a session CCC Counseling session at baseline only. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
Provided is a compound which is useful as an active ingredient for a pharmaceutical composition for treating cancer associated with the activation of an immunocyte or cancer having resistance to an anti-PD-1 antibody/anti-PD-L1 antibody therapy. The present inventors have studied about a compound useful as an active ingredient for a pharmaceutical composition for treating cancer associated with the activation of an immunocyte or cancer having resistance to an anti-PD-1 antibody/anti-PD-L1 antibody therapy. As a result, it is confirmed that a heteroaryl carboxamide compound has a DGK? (DGKzeta) inhibiting activity, and this confirmation leads to the accomplishment of the present invention. The heteroaryl carboxamide compound according to the present invention has a DGK? inhibiting activity, and can be used as a therapeutic agent for cancer associated with the activation of an immunocyte or cancer having resistance to an anti-PD-1 antibody/anti-PD-L1 antibody therapy.
Sham acupuncture refers to acupuncture at sham points. Sham acupuncture will be given on the basis of usual care. A total of 12 sessions of sham acupuncture will be given over a period of 4 weeks.
INTRODUCTION: Perioperative therapy has gained significant importance in patients with advanced melanoma. Currently, there is little data on the routine use of preoperative immunotherapy in metastatic melanoma outside clinical trials. This study aimed to evaluate the effectiveness of preoperative treatment in patients with borderline resectable stage III or IV melanoma as well as in oligoprogressing stage IV cases; the secondary aim is to describe the safety of surgery after immunotherapy.
MATERIALS AND METHODS: Since 1/Jan/2016 seventeen patients were treated with curative intent neoadjuvant immunotherapy, surgery, and adjuvant immunotherapy, while nineteen patients were operated due to oligoprogression while treted with immunotherapy. Survival was analyzed using the Kaplan-Meier method and association between variables was tested using the chi-squared test.
RESULTS: R0 resection was achieved in 76.5 % of cases after neoadjuvant immunotherapy. 24 % of patients achieved objective RECIST response and 35 % complete or major pathological response. At the median follow-up time of 51.4 months, 64.7 % of patients were free of PD after perioperative treatment, while 3-year RFS and OS rates were 68 % and 80.9 %, respectively. R0 resection was achieved in 73.7 % of oligo-progressing nodules. The median time to PD on immunotherapy after the first oligoprogression was 10.3 months. Immunotherapy did not result in any unexpected surgical complications. No patient died during preoperative treatment due to immunotherapy toxicity or disease progression.
CONCLUSIONS: We confirmed treatment safety and long-term disease control after perioperative immunotherapy. Patients with borderline resectable melanoma should be referred to reference centers using neoadjuvant immunotherapy.
GLP-1 is an incretin hormone that mediates glucose-stimulated insulin secretion.Accumulating data from both animal and human studies confirmed a beneficial effect of GLP-1 on myocardium, endothelium and vasculature, suggesting the potential ameliorative effect of peripheral atherosclerosis. In our preliminary studies shown that liraglutide, a long-acting GLP-1R agonist (GLP1RA), stimulate endothelial proliferation and angiogenesis. The study aims to test the hypothesis that sustained activation of the GLP-1R enhances microvascular perfusion, promotes angiogenesis, leading to increased walking distance and limb perfusion in diabetes patients with peripheral arterial disease (PAD). Eligible patients will be randomized 1:1 to with or without liraglutide treatment by a 6-month follow-up. The primary endpoints are the change in initial and absolute claudication distance and assessment of limb ischemia at 6 months compared with baseline. This trial will collect important mechanistic and clinical information on the safety and efficacy of liraglutide in T2DM patients with PAD.
Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
PURPOSE: A physiologically active composition containing an Aster yomena extract as an active ingredient is provided to ensure antioxidative and anticancer effects and to remove nitrite. CONSTITUTION: A physiologically active composition contains an Aster yomena extract as an active ingredient and has antioxidative, anticancer, and nitrite removal effects. The extract is a methanol extract which is prepared at 95 deg. C for 3-48 hours. The phenol content is increased by extracting Aster yomena at 95 deg. C for 6 hours.
The study will be a prospective randomized double-blind placebo-controlled trial of mirabegron for medical expulsive therapy (MET) in patients with a CT scan-proven ureteral stone between 4 to 10 mm undergoing expectant management. Subjects will be distributed at a 1:1 ratio between the control and treatment groups. The treatment group will receive mirabegron and the control groups will receive a placebo. Both groups will receive analgesics and hydration will be recommended. All subjects will then be followed for 30 days to determine the proportion of subjects with spontaneous passage. Patients will record narcotic usage and pain scores during this time. If there is stone persistence in the ureter based on imaging (CT scan of the abdomen and pelvis versus renal ultrasound plus KUB), then the patient will undergo ureteroscopy with stent placement. In these patients, treatment will continue while the stent is in place and patients will fill out a validated questionnaire regarding stent pain.
Partial depletion of RLIP76 in p53 deficient living subject has shown many health benefits. In one embodiment, partial Rlip depletion is used to prevent or treat cancer in p53 deficient living subjects. In another embodiment, partial Rlip depletion is used for reversion of DNA-methylation abnormalities caused by the lack of p53 to normal in p53 deficient living subjects. In yet another embodiment, partial Rlip depletion is used in reduction of blood glucose, insulin-resistance, hyperlipidemina, or any combination thereof in p53 deficient living subjects. Methods of using liposome containing anti-sense nucleic acid or double stranded siRNA to partially deplete RLIP76 and thus treat p53 deficient subject are disclosed. The approaches described herein can be especially helpful in preventing cancer in Li-Fraumeni patients.
Systems and methods presented herein relate to managing ambulatory medical device data access. A computing system of a networked computing environment can establish a direct end-to-end data connection to an ambulatory medical device via a wireless wide area network. A public key of the computing system may be transmitted to the ambulatory medical device permitting the ambulatory medical device to encrypt data to be transmitted to the computing system. The computing system may receive, via the direct end-to-end data connection, encrypted data from the ambulatory medical device, and upon decrypting the data can generate a therapy report based at least in part on the therapy data. This therapy report may include time-series therapy data relating to the therapy delivered by the ambulatory medical device over a particular time period. The computing system can restrict access to the therapy report to authorized users.
Purpose: The aim of the present study was to investigate the influence of players' relative age, maturation-related characteristics, and motor performance tests on two different stages of talent selection (regional and national level) in youth elite basketball. Methods: Relative age, maturation-related variables (height, weight, maturity offset, maturity timing) and motor performance (Countermovement jump, Standing long jump, Modified agility T-test, Linear sprint 20 m) of N = 68 male youth basketball players (Mage = 14.39 ± 0.28 years) were assessed during the initial selection tournament for the German U15 national team. Pre-selection biases regarding relative age and maturity timing on the regional level were investigated utilizing one-sample t-tests. Differences in relative age, maturation-related characteristics and motor performance between players selected (n = 27) and non-selected (n = 41) for the youth national team were examined via independent samples' t-tests and logistic regression analyses. Results: Strong pre-selection biases toward early-born and early-maturing players were confirmed on the regional level. Significant advantages in height and weight and higher values in maturity offset and maturity timing were found for selected players. Among the motor variables, only Countermovement jump performance was significantly better in selected players. When controlling for relative age and biological maturation regression models including motor performance variables did not significantly discriminate players' selection status. Conclusion: Coaches working in national, but also preceding selection stages (regional and club level) should raise their awareness to relative age and biological maturation when evaluating players' potential and current (motor) performance.
PURPOSE: A cosmetic composition for skin whitening containing Cynanchum atratum extract and pregnane compound isolated from the extract is provided to ensure excellent skin whitening and use in medicinal and pharmaceutical product for treating or preventing hyperpigmentation. CONSTITUTION: A cosmetic composition for skin whitening containing cosmetically effective amount of white rice extract and cosmetically acceptable carrier. The white rice extract is methanol solvent extract. The white rice extract is skin whitening fraction of methylene chloride solvent of methanol solvent extract. A pharmaceutical composition for preventing or treating hyperpigmentary disorder contains pharmaceutically effective amount of white rice extract and pharmaceutically acceptable carrier. A novel pregnane compound of chemical formula 1 or 2 is isolated from white rice extract.
The participants are randomly assigned to this group completes The Power as Knowing Participation in Change (PKPCT) and the Guided Imagery Intervention as described above. The study measures are completed upon entry and 21 days after entry and include the PKPCT and the SF-36v2.
Group 1a comprises healthy volunteers who will complete a Cardiac MRI without contrast. A subset of healthy volunteers will have a repeat MRI at Children's Hospital of Orange County.
Renal transplantation is widely recognized as the treatment of choice for children with end-stage renal disease (ESRD). Although outcomes of renal transplantation in children have improved during the past decade, success has been limited by both non-specific tolerance and the complications associated with immunosuppressants. Steroids and calcineurin inhibitors have the most toxic side effects. Use of sirolimus for immunosuppression has not been associated with as many complications. Recent studies from Europe have demonstrated that sirolimus can be combined with MMF and steroids to provide excellent graft survival in the absence of calcineurin inhibitors. Steroid side-effects can be lessened by tapering the steroid dose to an every-other-day schedule. This protocol tests whether immunosuppression by IL-2r antibody, sirolimus, MMF, and alternate-day steroids will provide comparable graft survival for living donor recipients, compared to current immunosuppression, but with reduced complications of calcineurin inhibitors.

Evaluations prior to transplantation include a complete history and physical examination, CBC, liver function tests, and antibodies for CMV, EBV, HIV, HbsAG, and HCV. All appropriate vaccinations are provided before transplantation. Transplant recipients receive immunosuppression therapy using antibody induction (daclizumab), corticosteroids, mycophenolate mofetil, and sirolimus. Serum sirolimus levels are measured so that doses can be adjusted to maintain certain blood levels of the drug. Bactrim and ganciclovir are given for infection prophylaxis. If the patient has consistent high levels of fasting cholesterol, treatment with lipitor may be given. A transplant biopsy is performed at the time of the transplant and at 3, 6, and 12 months post transplantation and at times when a rejection is suspected. A radionuclide GFR is done at the same time points, and at 1, 24, and 36 months. The protocol biopsies, blood, and urine samples will be analyzed by genomic methods to determine differences in gene expression post transplantation. In the event of a first acute rejection, patients are treated with Solu-Medrol for 3 consecutive days. A second rejection (at the discretion of the transplant center) or severe rejection (Banff Grade 3) is treated with antibody therapy and, after a second or severe rejection, the immunosuppressant regimen is changed. Patients are followed for 36 months with routine physical examinations and laboratory assessments.